The health body said up to 14,000 people could benefit from Ritlecitinib, which is also known as Litfulo, and people over 12 with severe alopecia should have access to drug, made by Pfizer. NICE initially rejected the drug last year, but said it was able to reverse its decision f...
She also said there was a lack of long-term evidence on what happens to young people prescribed blockers - adding that GIDS had not gathered routine and consistent data, meaning it was "not possible to accurately track the outcomes and pathways that children and young people take through...
Evaluation is crucial to determine how to properly deliver complex treatment pathways to achieve the best clinical outcomes and acceptability. The current movement within the NHS towards a more user-centred service where the Government is keen that any modernisation of the NHS involves putting patients...
The lecture will be at the Exploratorium Bay Observatory Gallery at the back of the museum. The special event entrance is through the gate on the outside of building, past the main entrance (as depicted in the map). Someone should be out front helping guide (the museum itself will not be...